Nothing but respect and maybe bad NSLCL is already in the price. What probably isn't factored into the price at 100% is the tremendous amount of dilution it will take to get the other drug indications into a phIII or into position to be partnered. Especially, with our team's seemingly inability to get anything partnered.
Another year at x million per quarter. What say $20M for the year at these prices = another 40M shares or possible 40% dilution. Doesn't sound like that is a recipe for a success. It is no secret that we need a bit of good news and a change in pps to reverse the action.
News 
Market Data 
Discover 
